Latest News and Press Releases

IRVINE, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing Novel, patented copy number index (CNI) therapy monitoring test...

Data shows broad adoption and real-world clinical utility of its DetermaRx™ test for early-stage lung cancer IRVINE, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE...

Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and...

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

Aligns Oncocyte with one of China’s fastest growing NGS-based cancer therapy selection companies; China is considered to be the world’s largest early-stage lung cancer market Exclusive agreement...

IRVINE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

Data demonstrate that DetermaIO™ can be run successfully using limited tissue from small biopsy specimens, overcoming the significant challenges associated with tissue availability for molecular...